Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.
作者信息
Brown Jennifer R, Zelenetz Andrew, Furman Richard, Lamanna Nicole, Mato Anthony, Montillo Marco, O'Brien Susan, Dubowy Ronald, Gu Lin, Munugalavadla Veerendra, Robak Tadeusz, Hillmen Peter
机构信息
Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA, USA.
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Leukemia. 2020 Dec;34(12):3404-3407. doi: 10.1038/s41375-020-0974-y. Epub 2020 Jul 12.
Abstract
摘要
相似文献
1
Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.接受idelalisib治疗的慢性淋巴细胞白血病患者发生3/4级转氨酶升高的危险因素。
Leukemia. 2020 Dec;34(12):3404-3407. doi: 10.1038/s41375-020-0974-y. Epub 2020 Jul 12.
2
Idelalisib for chronic lymphocytic leukemia.idelalisib用于治疗慢性淋巴细胞白血病。
Clin Adv Hematol Oncol. 2014 Dec;12(12):846-8.
3
Idelalisib approved for three blood cancers.idelalisib获批用于三种血癌。
Am J Health Syst Pharm. 2014 Sep 1;71(17):1430. doi: 10.2146/news140061.
4
Idelalisib, ibrutinib show benefits in CLL.idelalisib和ibrutinib在慢性淋巴细胞白血病中显示出疗效。
Cancer Discov. 2014 Apr;4(4):382. doi: 10.1158/2159-8290.CD-NB2014-025. Epub 2014 Feb 20.
5
Idelalisib: targeting PI3Kδ in B-cell malignancies.idelalisib：靶向B细胞恶性肿瘤中的PI3Kδ
Lancet Oncol. 2014 Mar;15(3):e108. doi: 10.1016/s1470-2045(14)70052-x.
6
Promising results Halt phase III studies of idelalisib.喜人的结果使idelalisib的III期研究暂停。
Am J Manag Care. 2014 Feb;20(2 Spec No.):E9.
7
Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia.idelalisib可迅速改善慢性淋巴细胞白血病患者的血小板功能测试。
Br J Haematol. 2018 Dec;183(5):825-828. doi: 10.1111/bjh.15052. Epub 2018 Jan 7.
8
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.依鲁替尼治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤。
Future Oncol. 2016 Sep;12(18):2077-94. doi: 10.2217/fon-2016-0003. Epub 2016 Jun 21.
9
Sequential disseminated aspergillosis and pulmonary tuberculosis in a patient treated by idelalisib for chronic lymphocytic leukemia.一例接受idelalisib治疗慢性淋巴细胞白血病患者发生的序贯播散性曲霉病和肺结核
Med Mal Infect. 2017 Jun;47(4):293-296. doi: 10.1016/j.medmal.2016.10.001. Epub 2016 Nov 3.
10
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.依鲁替尼，一种磷酸肌醇 3-激酶 p110δ 的抑制剂，用于治疗复发/难治性慢性淋巴细胞白血病。
Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10.
引用本文的文献
1
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors.治疗起始时循环 Th17 细胞预测 PI3Kδ 抑制剂的自身免疫毒性。
Blood Cancer J. 2023 Feb 2;13(1):22. doi: 10.1038/s41408-023-00788-9.
2
Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.依鲁替尼可减少复发难治性慢性淋巴细胞白血病患者的调节性 T 细胞并激活辅助性 T 细胞 17 细胞分化。
Br J Haematol. 2022 Apr;197(2):207-211. doi: 10.1111/bjh.18053. Epub 2022 Feb 15.
3
The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.磷脂酰肌醇 3-激酶抑制剂在慢性淋巴细胞白血病治疗中的应用进展。
Hematol Oncol Clin North Am. 2021 Aug;35(4):807-826. doi: 10.1016/j.hoc.2021.03.009. Epub 2021 May 27.
4
Phosphatidylinositol 3 Kinase δ Inhibitors: Present and Future.磷脂酰肌醇 3 激酶 δ 抑制剂：现状与未来。
Cancer J. 2019 Nov/Dec;25(6):394-400. doi: 10.1097/PPO.0000000000000414.
5
DUO delivers for duvelisib.度维利塞布表现出色。
Blood. 2018 Dec 6;132(23):2422-2424. doi: 10.1182/blood-2018-10-879650.
6
Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.伊德拉利昔单抗治疗慢性淋巴细胞白血病和滤泡性淋巴瘤相关不良事件的管理：多学科立场文件。
Hematol Oncol. 2019 Feb;37(1):3-14. doi: 10.1002/hon.2540. Epub 2018 Sep 5.
Zotero 插件